LZU‐WZLYCS01 is designed to achieve precise drug delivery through FGFR3 targeting while simultaneously leveraging A2‐mediated MAD2L1 inhibition to eradicate tumor cells, providing a promising therapeutic strategy to address these molecularly driven challenges. Here, MAD2L1 is linked to neoplasm.